ASA

:   American Society of Anesthesiologists

BCI

:   Bladder Cancer Index urinary/sexual/bowel

BIS

:   body image scale

BMI

:   body mass index

CARE

:   Convalescence and Recovery Evaluation

CI

:   confidence interval

ECUD

:   extracorporeal urinary diversion

ERAS

:   enhanced recovery after surgery

FACT‐VCI

:   Functional Assessment of Cancer Therapy‐Vanderbilt Cystectomy Index

ICUD

:   intracorporeal urinary diversion

M--H

:   Mantel--Haenszel test

NR

:   not reported

NRCT

:   non‐randomized comparative study

ORC

:   open radical cystectomy

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta‐Analyses

QLQ‐C30

:   Quality of Life Questionnaire Core 30

QOL

:   quality of life

RARC

:   robot‐assisted radical cystectomy

RC

:   radical cystectomy

RCTs

:   randomized controlled studies

ROBINS‐I

:   risk of bias in non‐randomized studies of interventions

RR

:   relative risk

SD

:   standard deviation

UTI

:   urinary tract infection

WMD

:   weighted mean difference

Introduction {#iju14005-sec-0001}
============

ORC with pelvic lymph node dissection and urinary diversion is the standard treatment for patients with muscle‐invasive bladder cancer and those with very high‐risk non‐muscle‐invasive bladder cancer.[1](#iju14005-bib-0001){ref-type="ref"} ORC continues to be associated with a high rate of mortality and morbidity, such as perioperative UTIs, thrombosis and ileus, which cause prolonged hospital stay and affect the patients' health‐related QOL. Indeed, \>60% of patients treated with ORC experience at least one perioperative complication, and approximately 20% experience a high‐grade complication within 90 days of the surgery.[2](#iju14005-bib-0002){ref-type="ref"} Although progress has resulted from changes in perioperative management, such as the ERAS, a proposed strategy to reduce perioperative complications has been to minimize the invasiveness of the surgical procedures, such as through the performance of a RARC.

Initial non‐randomized retrospective studies showed significant advantages to RARC over ORC, such as lower estimated blood loss, lower blood transfusion rates, shorter length of stay and lower rate of postoperative complications.[3](#iju14005-bib-0003){ref-type="ref"} Conversely, early randomized controlled trials failed to find any differences in complications at 90 days between RARC and ORC.[4](#iju14005-bib-0004){ref-type="ref"}, [5](#iju14005-bib-0005){ref-type="ref"} As the last meta‐analysis on this subject was carried out in 2017,[6](#iju14005-bib-0006){ref-type="ref"} a significant body of novel data including both randomized (RCTs) and NRCTs have emerged, adding new evidence to the topic.[2](#iju14005-bib-0002){ref-type="ref"}, [5](#iju14005-bib-0005){ref-type="ref"}, [7](#iju14005-bib-0007){ref-type="ref"}, [8](#iju14005-bib-0008){ref-type="ref"}

To assess the differential perioperative complications and health‐related QOL outcomes between RARC and ORC, we carried out an up‐to‐date systematic review and meta‐analysis of the literature comparing complications rates, as well as health‐related QOL outcomes of patients treated with RARC, with those of patients treated with ORC. We analyzed the data from the RCTs and the NRCTs separately to unmask potential bias arising from study design.

Methods {#iju14005-sec-0002}
=======

The protocol has been registered in the International Prospective Register of Systematic Reviews database (PROSPERO: CRD42018108001). The PRISMA checklist is reported in [Table S1](#iju14005-sup-0004){ref-type="supplementary-material"}.

Literature search and inclusion/exclusion criteria {#iju14005-sec-0003}
--------------------------------------------------

The present systematic review and meta‐analysis were carried out according to the PRISMA statement[9](#iju14005-bib-0009){ref-type="ref"} and the Cochrane Handbook for Systematic Reviews of Interventions.[10](#iju14005-bib-0010){ref-type="ref"} A comprehensive literature search using the electronic databases (MEDLINE, Web of Science, Scopus and Cochrane Library) was carried out on 10 August 2018 to retrieve the articles published comparing postoperative complications and health‐related QOL of patients treated with RARC with that of those treated with ORC. All full text papers were assessed and excluded with reasons when deemed inappropriate after screening based on the study title and abstract. Two reviewers carried out this process independently. Disagreements were resolved by a third party. The following string terms were used: (bladder cancer) AND (postoperative complication OR intraoperative complication OR perioperative complication OR postoperative morbidity OR postoperative mortality OR quality of life OR length of stay) AND (robot‐assisted radical cystectomy OR da Vinci radical cystectomy OR robotic radical cystectomy*)*.

Studies were included if they compared RARC with ORC and reported at least one postoperative complication outcome or health‐related QOL assessment between both arms in RCTs or NRCTs that included retrospective observational or cohort studies. If there were multiple articles written by the same group based on a similar patient cohort, only the largest or most recently published study was included. Review articles, editorials, comments and meeting abstracts were excluded. References of included manuscripts were scanned for additional studies of interest.

Data extraction {#iju14005-sec-0004}
---------------

Two authors independently extracted the required data. The baseline patient characteristics, postoperative complication rate, and health‐related QOL assessment data of both RARC and ORC arms in all eligible studies were collected. The outcomes of interest in this meta‐analysis were postoperative complication rates within 30 and 90 days, types of complications, and other perioperative parameters, such as operative time, estimated blood loss, blood transfusion rate and length of hospital stay, as well as health‐related QOL scores. All discrepancies regarding data extraction were resolved by consensus or finally decided by Delphi consensus with other authors.

Statistical analysis {#iju14005-sec-0005}
--------------------

The WMD and RR with 95% CIs were used as the summary variables for continuous and dichotomous outcomes, respectively. If studies only reported continuous data as the median and range or interquartile range, the mean and SDs were calculated according to Hozo *et al*.[11](#iju14005-bib-0011){ref-type="ref"} Statistical heterogeneity among studies was calculated using the *I* ^2^ statistics. The χ^2^‐test and *I* ^2^ statistics with significance set at *P* \<0.10 and *I* ^2^ \<50%, respectively, were used to assess statistical heterogeneity among studies. If there was a lack of heterogeneity, fixed effects models were used for meta‐analysis. Random effects models were used in cases of heterogeneity. Statistical analyses were carried out using Review Manager (RevMan‐Computer program, Version 5.3 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Risk of bias {#iju14005-sec-0006}
------------

For RCTs, we used the Cochrane Risk of Bias Tool for RCTs.[10](#iju14005-bib-0010){ref-type="ref"} For NRCTs, we used the ROBINS‐I tool.[12](#iju14005-bib-0012){ref-type="ref"} Two authors independently assessed the risk of bias in each study. All discrepancies regarding the risk of bias were resolved by consensus between two authors.

Results {#iju14005-sec-0007}
=======

Study selection and characteristics {#iju14005-sec-0008}
-----------------------------------

Overall, 525 articles were identified for an initial assessment (Fig. [1](#iju14005-fig-0001){ref-type="fig"}); 187 duplicates were removed. Then, 230 and 71 articles were excluded after title and abstract assessment, and full text reading, respectively. Finally, 37 and 34 studies that reported postoperative complications and health‐related QOL outcomes between RARC and ORC were included for qualitative and quantitative analyses, respectively. The general characteristics of the eligible studies are summarized in Table [1](#iju14005-tbl-0001){ref-type="table"}. The present systematic review includes six RCTs[2](#iju14005-bib-0002){ref-type="ref"}, [4](#iju14005-bib-0004){ref-type="ref"}, [5](#iju14005-bib-0005){ref-type="ref"}, [13](#iju14005-bib-0013){ref-type="ref"}, [14](#iju14005-bib-0014){ref-type="ref"}, [15](#iju14005-bib-0015){ref-type="ref"} comprising 581 patients, and 31 NRCTs[7](#iju14005-bib-0007){ref-type="ref"}, [8](#iju14005-bib-0008){ref-type="ref"}, [16](#iju14005-bib-0016){ref-type="ref"}, [17](#iju14005-bib-0017){ref-type="ref"}, [18](#iju14005-bib-0018){ref-type="ref"}, [19](#iju14005-bib-0019){ref-type="ref"}, [20](#iju14005-bib-0020){ref-type="ref"}, [21](#iju14005-bib-0021){ref-type="ref"}, [22](#iju14005-bib-0022){ref-type="ref"}, [23](#iju14005-bib-0023){ref-type="ref"}, [24](#iju14005-bib-0024){ref-type="ref"}, [25](#iju14005-bib-0025){ref-type="ref"}, [26](#iju14005-bib-0026){ref-type="ref"}, [27](#iju14005-bib-0027){ref-type="ref"}, [28](#iju14005-bib-0028){ref-type="ref"}, [29](#iju14005-bib-0029){ref-type="ref"}, [30](#iju14005-bib-0030){ref-type="ref"}, [31](#iju14005-bib-0031){ref-type="ref"}, [32](#iju14005-bib-0032){ref-type="ref"}, [33](#iju14005-bib-0033){ref-type="ref"}, [34](#iju14005-bib-0034){ref-type="ref"}, [35](#iju14005-bib-0035){ref-type="ref"}, [36](#iju14005-bib-0036){ref-type="ref"}, [37](#iju14005-bib-0037){ref-type="ref"}, [38](#iju14005-bib-0038){ref-type="ref"}, [39](#iju14005-bib-0039){ref-type="ref"}, [40](#iju14005-bib-0040){ref-type="ref"}, [41](#iju14005-bib-0041){ref-type="ref"}, [42](#iju14005-bib-0042){ref-type="ref"}, [43](#iju14005-bib-0043){ref-type="ref"}, [44](#iju14005-bib-0044){ref-type="ref"} comprising 48 392 patients published between 2010 and 2018. Of these, 20 studies enrolled patients from North America, nine from Europe and eight from Asia. Four RCTs and 19 NRCTs had only patients treated with ECUD. Just five NRCTs included patients treated with ICUD. Other studies included mix cohorts with ECUD/ICUD or did not report on the type of urinary diversion. Three studies compared the complication rates between RARC and ORC only in patients who received a neobladder. Perioperative parameters are shown in Table [2](#iju14005-tbl-0002){ref-type="table"}. Operative time and length of stay were reported in 31 and 30 studies, respectively. Estimated blood loss and transfusion rate were reported in 31 and 20 studies, respectively. Postoperative complications after RARC and ORC are shown in Table [3](#iju14005-tbl-0003){ref-type="table"}; 27 studies investigated complication rates within 30 or 90 days. The mortality rate within 90 days was reported in 15 studies. Postoperative health‐related QOL is shown in Table [4](#iju14005-tbl-0004){ref-type="table"}. Just three RCTs and three NRCTs reported comparisons of health‐related QOL changes before and after RARC and ORC. It was not possible to carry out a meta‐analysis of the health‐related QOL outcomes due to the heterogeneity of health‐related QOL assessment tools between included studies. The risk of bias tables in RCTs and NRCTs are shown in [Figure S1](#iju14005-sup-0001){ref-type="supplementary-material"} and [Table S2](#iju14005-sup-0005){ref-type="supplementary-material"}, respectively.

![PRISMA flow chart of the systematic review and meta‐analysis.](IJU-26-760-g001){#iju14005-fig-0001}

###### 

Characteristics of the included studies

  Author                 Region    Arm        No. patients   Age, years (mean or median)   BMI (mean or median)   ASA score (mean or median)   Urinary diversion (corporeal)   Rate of neobladder (%)
  ---------------------- --------- ---------- -------------- ----------------------------- ---------------------- ---------------------------- ------------------------------- ------------------------
  Randomized study                                                                                                                                                             
  Nix 2010               USA       RARC/ORC   21/20          67.4/69.2                     27.5/28.4              2.71/2.70                    ECUD                            33.3/30
  Parekh 2013            USA       RARC/ORC   20/20          69.5/64.5                     27.6/28.3              3.0/3.0                      NR                              NR
  Messer 2014            USA       RARC/ORC   20/20          69.5/64.5                     27.6/28.3              3.0/3.0                      NR                              NR
  Bochner 2015           USA       RARC/ORC   60/58          66/65                         27.9/29.0              2.73/2.73                    ECUD                            55/55
  Khan 2016              UK        RARC/ORC   20/20          68.6/66.6                     27.5/27.4              1.85/1.85                    ECUD                            10/15
  Parekh 2018            USA       RARC/ORC   150/152        70/67                         27.8/28.2              NR                           ECUD                            24/20
  Non‐randomized study                                                                                                                                                         
  Ng 2010                USA       RARC/ORC   83/104         70.9/67.2                     26.3/27.2              43.3/48.1 (%, 3≤)            ECUD                            31.3/27.9
  Richard 2010           USA       RARC/ORC   35/35          65/66                         27/26                  89/77 (%, 3≤)                ECUD                            8.6/0
  Gondo 2012             Japan     RARC/ORC   11/15          68.9/69.7                     21.8/24.2              NR                           ECUD                            36.4/40.0
  Khan 2012              UK        RARC/ORC   48/52          66.5/65                       NR                     18.8/48.1 (%, 3≤)            ECUD                            12.5/9.6
  Styn 2012              USA       RARC/ORC   50/100         66.6/65.6                     29.8/29.6              54/57 (%, 3≤)                ECUD                            28/28
  Sung 2012              Korea     RARC/ORC   35/104         62.2/65.9                     23.1/22.4              8.6/7.7 (%, 3≤)              ECUD                            62.9/18.3
  Kander 2013            USA       RARC/ORC   100/100        67/67                         26.5/27.1              78/73 (%, 3≤)                ECUD                            3.0/12.0
  Knox 2013              USA       RARC/ORC   58/84          65.9/67.1                     28.6/28.9              88/90 (%, 3≤)                ECUD                            8.6/10.7
  Maes 2013              USA       RARC/ORC   14/14          71.0/67.6                     27.3/27.2              NR                           ECUD                            0/0
  Aboumohamed 2014       USA       RARC/ORC   82/100         71.5/71.5                     27.8/27.9              45.1/66.0 (%, 3≤)            ICUD/ECUD                       0/0
  Leow 2014              USA       RARC/ORC   2667/40 980    NR                            NR                     NR                           NR                              8.5/6.1
  Musch 2014             Germany   RARC/ORC   100/42         71.4/69.0                     27/27                  NR                           ECUD                            22.0/16.7
  Niegisch 2014          Germany   RARC/ORC   64/79          68/71                         24/26                  2.0/3.0                      ECUD                            34.3/32.9
  Koupparis 2015         UK        RARC/ORC   102/56         68.2/66.4                     NR                     26.5/8.9 (%, 3≤)             ICUD                            10.8/7.1
  Bak 2016               Korea     RARC/ORC   42/70          70/70                         22.2/22.3              2.0/2.0                      ECUD                            26.2/1.4
  Cusano 2016            USA       RARC/ORC   121/92         65.9/67.8                     28.2/28.4              3.0/3.0                      ICUD/ECUD                       30.0/25.0
  Gandaglia 2016         Belgium   RARC/ORC   138/230        70/70.9                       26.1/26.0              39.1/38.7 (%, 3≤)            ICUD/ECUD                       15.2/62.5
  Iwamoto 2016           Japan     RARC/ORC   20/40          73/72.5                       23.1/21.7              NR                           ECUD                            15.0/22.5
  Li 2016                USA       RARC/ORC   57/267         67.0/65.7                     NR                     NR                           NR                              NR
  Satkunasivam 2016      USA       RARC/ORC   28/79          63.5/67                       NR                     60.7/71.8 (%, 3≤)            ICUD                            100/100
  Winters 2016           USA       RARC/ORC   29/58          79.2/79.6                     26.9/26.5              NR                           ECUD                            NR
  Kingo 2017             Denmark   RARC/ORC   38/125         68.3/72.3                     27.3/26.4              5.3/23.2 (%, 3≤)             ICUD                            100/100
  Koie 2017              Japan     RARC/ORC   29/196         65/69                         NR                     NR                           NR                              NR
  Muto 2017              Japan     RARC/ORC   21/28          66.8/70.3                     23.7/23.1              NR                           ECUD                            28.6/3.6
  Sharma 2017            USA       RARC/ORC   65/407         70.9/70.2                     27.8/28.0              49.2/56.0 (%, 3≤)            ECUD                            10.8/13.8
  Flamiatos 2018         USA       RARC/ORC   100/149        NR                            27.8/28.2              NR                           ECUD                            16.0/24.8
  Kukreja 2018           USA       RARC/ORC   100/96         66.2/66.2                     28.9/29.4              NR                           NR                              NR
  Simone 2018            Italy     RARC/ORC   64/46          62.5/63.6                     26.1/26.7              12.5/13.0 (%, 3≤)            ICUD                            100/100
  Tan 2018               UK        RARC/ORC   50/45          62.8/65.0                     27.0/29.7              38.0/13.3 (%, 3≤)            ICUD                            14.0/15.6
  Panwar 2018            India     RARC/ORC   24/54          57/58                         23.2/23.1              NR                           ECUD                            33.3/11.1
  Ram 2018               India     RARC/ORC   125/45         61.8/60.1                     24.2/23.9              NR                           ECUD                            36.0/28.9

John Wiley & Sons, Ltd
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Perioperative parameters after RARC and ORC

  Author                   Arms       Operation time, min (mean or median)   EBL, mL (mean or median)   Transfusion rate (%)   LOS, days (mean or median)
  ------------------------ ---------- -------------------------------------- -------------------------- ---------------------- ----------------------------
  Randomized studies                                                                                                           
  Nix 2010                 RARC/ORC   252/211.2                              258/575                    NR                     5.1/6.0
  Parekh 2013              RARC/ORC   300/285.5                              400/800                    40/50                  6.0/6.0
  Messer 2014              RARC/ORC   300/385.5                              400/800                    40/50                  6.0/6.0
  Bochner 2015             RARC/ORC   456/329                                516/676                    NR                     8.0/8.0
  Khan 2016                RARC/ORC   389/293                                585/808                    NR                     11.9/14.4
  Parekh 2018              RARC/ORC   428/361                                300/700                    24/45                  6.0/7.0
  Non‐randomized studies                                                                                                       
  Ng 2010                  RARC/ORC   375/357                                460/1172                   NR                     8.0/5.5
  Richards 2010            RARC/ORC   530/420                                350/1000                   17.1/71.4              7.0/8.0
  Gondo 2012               RARC/ORC   409/364                                657/1789                   0/40.0                 40.2/37.0
  Khan 2012                RARC/ORC   440/372                                381/1407                   4.2/57.7               9.8/19.3
  Styn 2012                RARC/ORC   455/349                                350/475                    4/24                   9.5/10.2
  Sung 2012                RARC/ORC   578/501                                448/1063                   11.4/56.7              28.9/27.1
  Kader 2013               RARC/ORC   451/393                                423/986                    15/47                  6.0/8.0
  Knox 2013                RARC/ORC   468/396                                276/1522                   5.2/80.1               6.3/10.8
  Maes 2013                RARC/ORC   383/268                                350/800                    7.1/28.6               12/11.4
  Aboumohamed 2014         RARC/ORC   382/250                                444/489                    NR                     8.0/7.0
  Leow 2014                RARC/ORC   386/338                                NR                         NR                     10.2/11.8
  Musch 2014               RARC/ORC   404/333                                300/600                    27.0/59.5              14.0/15.5
  Niegisch 2014            RARC/ORC   360/360                                300/800                    NR                     13.0/16.0
  Koupparis 2015           RARC/ORC   NR                                     NR                         19.6/41.1              NR
  Bak 2016                 RARC/ORC   480/405                                300/598                    23.8/45.7              19.0/21.0
  Cusano 2016              RARC/ORC   508/403                                450/600                    21.5/39.1              8.0/9.0
  Gandaglia 2016           RARC/ORC   330/185                                300/300                    9.4/16.1               13.0/20.0
  Iwamoto 2016             RARC/ORC   512/523                                227/935                    10.0/92.5              NR
  Winters 2016             RARC/ORC   413/370                                257/641                    10.3/32.8              7.0/9.0
  Kingo 2017               RARC/ORC   311/272                                185/1823                   NR                     10.9/9.2
  Koie 2017                RARC/ORC   496/269                                330/1150                   NR                     NR
  Muto 2017                RARC/ORC   561/493                                458/1235                   NR                     19.0/25.5
  Sharma 2017              RARC/ORC   423/302                                350/800                    NR                     6/7
  Flamiatos 2018           RARC/ORC   411/371                                150/600                    NR                     5.0/7.0
  Kukreja 2018             RARC/ORC   NR                                     640/1158                   12.0/39.6              NR
  Simone 2018              RARC/ORC   NR                                     NR                         9.4/93.5               NR
  Tan 2018                 RARC/ORC   NR                                     NR                         NR                     13.6/20.1
  Panwar 2018              RARC/ORC   452/351                                552/512                    NR                     22.9/23.5
  Ram 2018                 RARC/ORC   364/355                                229/122                    NR                     10.2/12.4

John Wiley & Sons, Ltd
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Postoperative complications after RARC and ORC

  Author                   Arm        Complication within 30 days (Clavien 1--5) (%)   Complication within 30 days (Clavien 3≤) (%)   Complication within 90 days (Clavien 1--5) (%)   Complication within 90 days (Clavien 3≤) (%)   Mortality rate within 90 days (%)   UTI rate (%)   Thrombosis rate (%)   Ileus rate (%)
  ------------------------ ---------- ------------------------------------------------ ---------------------------------------------- ------------------------------------------------ ---------------------------------------------- ----------------------------------- -------------- --------------------- ----------------
  Randomized studies                                                                                                                                                                                                                                                                                           
  Nix 2010                 RARC/ORC   33/50                                            NR                                             NR                                               NR                                             NR                                  9.5/5          4.8/0                 9.5/15
  Parekh 2013              RARC/ORC   25/25                                            NR                                             NR                                               NR                                             NR                                  NR             NR                    5/5
  Messer 2014              RARC/ORC   NR                                               NR                                             NR                                               NR                                             NR                                  NR             NR                    NR
  Bochner 2015             RARC/ORC   NR                                               NR                                             NR                                               21.7/20.7                                      0/1.7                               NR             8.3/8.6               NR
  Khan 2016                RARC/ORC   55/70                                            30/20                                          55/70                                            35/20                                          NR                                  35/15          5/0                   5/35
  Parekh 2018              RARC/ORC   NR                                               NR                                             67.3/69.1                                        22/22.4                                        2.7/2.6                             35.3/25.7      4.7/7.9               22/20.4
  Non‐randomized studies                                                                                                                                                                                                                                                                                       
  Ng 2010                  RARC/ORC   41.0/58.7                                        9.6/29.8                                       41.0/58.7                                        16.9/30.8                                      0/5.8                               16.9/16.3      6.0/3.8               15.7/20.2
  Richards 2010            RARC/ORC   60.0/65.7                                        20.0/25.7                                      NR                                               NR                                             NR                                  NR             NR                    NR
  Gondo 2012               RARC/ORC   54.5/73.3                                        0/6.7                                          NR                                               NR                                             NR                                  NR             NR                    NR
  Khan 2012                RARC/ORC   NR                                               NR                                             41.7/71.2                                        16.7/28.8                                      0/1.9                               2.1/5.8        0/5.8                 8.3/13.5
  Styn 2012                RARC/ORC   66.0/62.0                                        NR                                             NR                                               NR                                             0/3.0                               NR             NR                    22/25
  Sung 2012                RARC/ORC   NR                                               NR                                             62.9/74.0                                        8.6/23.1                                       2.9/2.9                             20/7.7         0/0                   25.7/29.8
  Kader 2013               RARC/ORC   NR                                               NR                                             36.0/58.0                                        10/22                                          1.0/0                               NR             NR                    NR
  Knox 2013                RARC/ORC   43.1/64.3                                        25.9/22.6                                      NR                                               NR                                             NR                                  1.7/6.0        1.7/3.6               10.3/7.1
  Maes 2013                RARC/ORC   NR                                               NR                                             NR                                               NR                                             NR                                  NR             NR                    57/58
  Aboumohamed 2014         RARC/ORC   NR                                               NR                                             NR                                               23.2/16.0                                      NR                                  NR             NR                    NR
  Leow 2014                RARC/ORC   NR                                               NR                                             59.7/56.8                                        19.8/17.0                                      2.5/3.8                             NR             NR                    NR
  Musch 2014               RARC/ORC   NR                                               NR                                             NR                                               NR                                             2.0/4.8                             29.0/28.6      3.0/19.0              8.0/38.1
  Niegisch 2014            RARC/ORC   NR                                               NR                                             NR                                               NR                                             3.1/3.8                             NR             NR                    NR
  Koupparis 2015           RARC/ORC   NR                                               NR                                             NR                                               NR                                             2.0/1.8                             NR             NR                    NR
  Bak 2016                 RARC/ORC   NR                                               NR                                             NR                                               NR                                             NR                                  21.4/20.0      0/0                   21.4/22.9
  Cusano 2016              RARC/ORC   NR                                               NR                                             47.1/54.3                                        18.2/20.7                                      NR                                  NR             NR                    NR
  Gandaglia 2016           RARC/ORC   NR                                               NR                                             60.1/44.3                                        15.9/20.4                                      1.4/0.9                             NR             NR                    NR
  Iwamoto 2016             RARC/ORC   100/100                                          5.0/10.0                                       NR                                               NR                                             NR                                  NR             NR                    0/12.5
  Winters 2016             RARC/ORC   NR                                               NR                                             37.9/37.9                                        NR                                             NR                                  NR             NR                    NR
  Kingo 2017               RARC/ORC   NR                                               26.3/17.6                                      NR                                               31.6/23.2                                      NR                                  21.1/9.6       0/4.8                 13.1/9.6
  Koie 2017                RARC/ORC   NR                                               0/0                                            NR                                               0/0                                            0/0                                 0/0            0/0                   17.2/3.8
  Muto 2017                RARC/ORC   NR                                               NR                                             NR                                               NR                                             NR                                  9.5/10.7       0/3.6                 4.8/3.6
  Sharma 2017              RARC/ORC   52.3/59.7                                        13.8/19.7                                      NR                                               NR                                             NR                                  NR             NR                    NR
  Flamiatos 2018           RARC/ORC   66.0/85.9                                        10.0/19.5                                      NR                                               NR                                             1.0/2.0                             NR             0/0.7                 NR
  Kukreja 2018             RARC/ORC   NR                                               NR                                             48.0/46.9                                        12.0/9.4                                       NR                                  NR             NR                    NR
  Simone 2018              RARC/ORC   39.1/45.7                                        6.3/2.2                                        NR                                               NR                                             NR                                  NR             NR                    NR
  Tan 2018                 RARC/ORC   64.0/71.1                                        22.0/23.9                                      78.0/86.0                                        26.0/30.2                                      6.0/7.0                             NR             NR                    47.5/31.1
  Panwar 2018              RARC/ORC   NR                                               NR                                             NR                                               NR                                             NR                                  0/0            0/0                   4.2/18.5
  Ram 2018                 RARC/ORC   39.2/55.6                                        15.2/22.2                                      NR                                               NR                                             NR                                  0/0            0/0                   9.6/11.1

John Wiley & Sons, Ltd
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Postoperative health‐related QOL change

<table><thead><tr class="header"><th>Author</th><th>QOL scale</th><th>Arm</th><th>QOL score baseline</th><th>QOL score at 1 month</th><th>QOL score at 3 months</th><th>QOL score at 6 months</th><th>QOL score at 9 months</th><th>QOL score at 12 months</th><th>QOL score overall</th></tr></thead><tbody><tr class="odd"><td>Randomized study</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Messer 2014</td><td>FACT‐VCI</td><td>RARC/ORC</td><td>119/135</td><td>NR</td><td><p>126.5/135.5</p><p><em>P</em> = 0.85</p></td><td><p>121.5/126</p><p><em>P</em> = 0.58</p></td><td><p>141.5/127.5</p><p><em>P</em> = 0.63</p></td><td><p>116/129</p><p><em>P</em> = 0.48</p></td><td>NR</td></tr><tr class="odd"><td>Bochner 2015</td><td>QLQ‐C3 (global QOL)</td><td>RARC/ORC</td><td>78/75</td><td>NR</td><td><p>77/72</p><p><em>P</em> = 0.4</p></td><td><p>76/78</p><p><em>P</em> = 0.5</p></td><td>NR</td><td>NR</td><td>NR</td></tr><tr class="even"><td>Parekh 2018</td><td>FACT‐VCI</td><td>RARC/ORC</td><td>120.1/120.9</td><td>NR</td><td>122.8/125.2</td><td>126.0/127.5</td><td>NR</td><td>NR</td><td>NR</td></tr><tr class="odd"><td>Non‐randomized study</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Aboumohamed 2014</td><td>BCI (urinary/sexual/bowel)</td><td><p>RARC</p><p>ORC</p></td><td><p>76.2/44.1/83.0</p><p>78.9/48.5/83.7</p></td><td><p>77.9/23.8/73.0</p><p>72.9/28.8/74.1</p></td><td><p>79.0/22.5/79.7</p><p>79.2/40.5/83.4</p><p>–/<em>P</em> = 0.08/–</p></td><td><p>81.2/28.7/80.4</p><p>84.6/35.3/26.3</p></td><td>NR</td><td><p>84.8/28.9/83.2</p><p>85.2/36.8/85.4</p></td><td><em>P</em> = 0.11/<em>P</em> = 0.047/<em>P</em> = 0.58</td></tr><tr class="odd"><td>BIS</td><td><p>RARC</p><p>ORC</p></td><td><p>2.1</p><p>2.9</p></td><td><p>4.8</p><p>4.9</p></td><td><p>5.8</p><p>4.8</p></td><td><p>6.6</p><p>3.9</p><p><em>P</em> = 0.24</p></td><td>NR</td><td><p>6.2</p><p>5.6</p></td><td><em>P</em> = 0.93</td><td></td></tr><tr class="even"><td>Li 2016</td><td>BCI (urinary/sexual/bowel)</td><td>RARC/ORC</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td><em>P</em> = 0.63/<em>P</em> = 0.37/<em>P</em> = 0.72</td></tr><tr class="odd"><td>Satkunasivam 2016</td><td>BCI (urinary)</td><td>RARC/ORC</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>69.5/73.7/<em>P</em> = 0.44</td></tr></tbody></table>

John Wiley & Sons, Ltd

Meta‐analysis {#iju14005-sec-0009}
-------------

### Comparison of perioperative parameters between RARC and ORC {#iju14005-sec-0010}

The forest plots (Fig. [2](#iju14005-fig-0002){ref-type="fig"}a) showed that RARC was associated with longer operative times in both RCTs (WMD: 74.16 min, 95% CI 35.25--113.07, *P* = 0.0002) and NRCTs (WMD: 78.04 min, 95% CI 52.78--103, *P* \< 0.00001). Figure [2](#iju14005-fig-0002){ref-type="fig"}b,c show that RARC was associated with a reduction in estimated blood loss in both RCTs (WMD: −299.62 mL, 95% CI −415.02 to −184.23, *P* \< 0.00001) and NRCTs (WMD: −539.71 mL, 95% CI −689.39 to −390.03, *P* \< 0.00001), as well as lower transfusion rates in RCTs (RR 0.52, 95% CI 0.39--0.71, *P* \< 0.0001) and NRCTs (RR 0.28, 95% CI 0.20--0.38, *P* \< 0.00001). RARC was associated with shorter length of stay in NRCTs (WMD: −2.34, 95% CI −3.48 to −1.19, *P* \< 0.0001), but not in RCTs (WMD: −0.62 days, 95% CI −1.29 to 0.05, *P* = 0.07; Fig. [2](#iju14005-fig-0002){ref-type="fig"}d). The χ^2^‐test and *I* ^2^‐test showed heterogeneity, except in pooled analysis of the transfusion rate in RCTs (Fig. [2](#iju14005-fig-0002){ref-type="fig"}c).

![Forest plots showing the comparison of (a) operative time, (b) blood loss, (c) transfusion rate and (d) length of stay between RARC and ORC.](IJU-26-760-g002){#iju14005-fig-0002}

### Comparison of postoperative complications within 30 and 90 days between RARC and ORC {#iju14005-sec-0011}

Within the first 30 postoperative days, there was no significant difference in complications with any Clavien grade and Clavien grade ≥3 (RR 0.78, 95% CI 0.53--1.16, *P* = 0.22 and RR 1.50, 95% CI 0.50--4.52, *P* = 0.47, respectively) between RARC and ORC in RCTs (Fig. [3](#iju14005-fig-0003){ref-type="fig"}a,b). Conversely, RARC was associated with lower complication rates with any Clavien grade (RR 0.82, 95% CI 0.75--0.90, *P* \< 0.0001) and Clavien grade ≥3 (RR 0.74, 95% CI 0.58--0.93, *P* = 0.01) in NRCTs (Fig. [3](#iju14005-fig-0003){ref-type="fig"}a,b). The χ^2^‐test and *I* ^2^‐test did not show any heterogeneity in all pooled analyses (Fig. [3](#iju14005-fig-0003){ref-type="fig"}a,b).

![Forest plots showing the comparison of (a) rates for any grade of complication within 30 days, (b) rates for grade ≥3 of complication within 30 days, (c) rates for any grade of complication within 90 days and (d) rates for grade ≥3 of complication within 90 days.](IJU-26-760-g003){#iju14005-fig-0003}

Within the first 90 postoperative days, there was no significant difference between RARC and ORC in complications with any Clavien grade and Clavien grade ≥3 both in RCTs (RR 0.95, 95% CI 0.82--1.10, *P* = 0.52 and RR 1.06, 95% CI 0.75--1.49, *P* = 0.74, respectively) and NRCTs (RR 0.90, 95% CI 0.78--1.04, *P* = 0.15 and RR 0.87, 95% CI 0.67--1.12, *P* = 0.27, respectively; Fig. [3](#iju14005-fig-0003){ref-type="fig"}c,d). The χ^2^‐test and *I* ^2^‐test showed significant heterogeneity in pooled analyses of NRCTs (Fig. [3](#iju14005-fig-0003){ref-type="fig"}c,d).

### Comparison of mortality within 90 days between RARC and ORC {#iju14005-sec-0012}

In RCTs, there was no significant difference between RARC and ORC in mortality rates within 90 days (RR 0.82, 95% CI 0.24--2.81, *P* = 0.75). Conversely, in NRCTs, RARC was associated with lower mortality rates within 90 days (RR 0.68, 95% CI 0.54--0.85, *P* = 0.0007; [Fig. S2](#iju14005-sup-0002){ref-type="supplementary-material"}). The χ^2^‐test and *I* ^2^‐test did not show any heterogeneity in all pooled analyses ([Fig. S2](#iju14005-sup-0002){ref-type="supplementary-material"}).

### Subgroup analyses of types of complications between RARC and ORC {#iju14005-sec-0013}

In RCTs, RARC was associated with higher overall UTI rates (RR 1.46, 95% CI 1.05--2.03, *P* = 0.03) compared with ORC without heterogeneity ([Fig. S3a](#iju14005-sup-0003){ref-type="supplementary-material"}). In NRCTs, ORC was associated with higher overall thrombolic event rates (RR 0.42, 95% CI 0.21--0.82, *P* = 0.01) compared with RARC without heterogeneity ([Fig. S3b](#iju14005-sup-0003){ref-type="supplementary-material"}). [Figure S3c](#iju14005-sup-0003){ref-type="supplementary-material"} showed that there was no significant difference in ileus rates between RARC and ORC in both RCTs and NRCTs (RR 0.89, 95% CI 0.60--1.32, *P* = 0.56 and RR 0.89, 95% CI 0.63--1.25, *P* = 0.49, respectively).

### Comparison of postoperative health‐related QOL between RARC and ORC {#iju14005-sec-0014}

Three RCTs investigated postoperative health‐related QOL (Table [4](#iju14005-tbl-0004){ref-type="table"}); two studies used the FACT‐VCI and one study used the European Organization for Research and Treatment of Cancer QLQ‐C30. Messer *et al*. compared changes in health‐related QOL score between the RARC and ORC patients at baseline, 3, 6, 9 and 12 months after surgery using the FACT‐VCI in 40 patients.[45](#iju14005-bib-0045){ref-type="ref"} They compared deviation from preoperative baseline health‐related QOL, and concluded there was no significant difference between RARC and ORC in FACT‐VCI scores (RARC/ORC median: 119/135 at baseline, 127/136 at 3 months, 122/126 at 6 months, 142/128 at 9 months and 116/129 at 12 months) with the exception of a 2.5‐point lower score in the ORC arm for physical well‐being at 6 months by multivariable linear regression analysis.

Parekh *et al*. used FACT‐VCI in 302 patients to compare health‐related QOL at baseline with those at 3 and 6 months postoperatively.[2](#iju14005-bib-0002){ref-type="ref"} They found no significant difference between the RARC and ORC arms at any time point for total FACT‐VCI sores including all domains (RARC/ORC mean total: 120/121 at baseline, 123/125 at 3 months and 126/128 at 6 months). They also reported that mean total FACT‐VCI scores at 6 months postoperatively (RARC/ORC 126/128) in both arms had significantly improved after surgery compared with those at baseline (RARC/ORC 120/121).

Bochner *et al*. compared health‐related QOL at baseline with those at 3 and 6 months postoperatively in RARC and ORC using QLQ‐C30.[4](#iju14005-bib-0004){ref-type="ref"} They showed that there were no statistical differences in QLQ‐C30 change from baseline to 3 and 6 months after surgery in any of the evaluated domains.

In NRCTs (Table [4](#iju14005-tbl-0004){ref-type="table"}), Aboumohamed *et al*. compared health‐related QOL between the RARC and ORC in 182 patients preoperatively, and at 1, 3, 6, 12, 18, 24 and 30 months postoperatively utilizing BCI and the European Organization for Research and Treatment of Cancer BIS questionnaires.[25](#iju14005-bib-0025){ref-type="ref"} They reported that the BCI and BIS scores were not statistically different between the RARC and ORC arms at any time point for urinary function (*P* = 0.11), bowel function (*P* = 0.58) and body image (*P* = 0.93), but the sexual function at all time points was better for patients treated with ORC (*P* = 0.047). Conversely, Li *et al*. used the BCI and CARE tools to compare health‐related QOL between RARC and ORC in 324 patients at baseline, 1, 3, 6 and 12 months after surgery.[34](#iju14005-bib-0034){ref-type="ref"} They found no differences in any of the BCI domains (urinary, sexual and bowel domains) at any time point between both procedures.

Discussion {#iju14005-sec-0015}
==========

Bladder cancer carries, due to the advanced age and high smoking rate of most patients, significant cumulative morbidity. RC, the standard of care for patients with muscle‐invasive and very high‐risk bladder cancer, is associated with a high rate of complications due to the complexity of the surgery itself and the inherent frailty of the patients.[36](#iju14005-bib-0036){ref-type="ref"} Minimal invasive surgeries, such as RARC, promise to reduce postoperative complications and maintain patients' health‐related QOL despite its higher cost and need for a learning curve.[46](#iju14005-bib-0046){ref-type="ref"} While we are awaiting more robust data on the oncological equivalence of RARC to ORC, its benefits regarding postoperative complication rates and health‐related QOL are intensively debated. In a meta‐analysis published in 2015, Novara *et al*. reported that the rates for any and major (≥3) Clavien grade of complications within 90 days were slightly in favor of RARC.[47](#iju14005-bib-0047){ref-type="ref"} In this updated systematic review and meta‐analysis, our aim was to examine the most up‐to‐date data on the differential impact of these two procedures on perioperative complications, mortality and health‐related QOL, with a focus on the difference between the results of RCTs and NRCTs. Although NRCTs are known to potentially lead to a more biased evaluation and reporting of outcomes compared with RCTs, they are often the basis of decision‐making and guideline recommendations, especially in surgical specialties.

In this systematic review and meta‐analysis, we analyzed six RCTs and 31 NRCTs comprising 581 and 48 392 patients, respectively, treated with RARC or ORC. Additionally, we carried out meta‐analysis of RCTs and NRCTs separately to ensure bias‐sensitive analyses. We found that compared with ORC, RARC was consistently associated with lower estimated blood loss, lower transfusion rates and longer operative times in both RCTs and NRCTs. For example, the largest RCT[2](#iju14005-bib-0002){ref-type="ref"} and the largest NRCT[22](#iju14005-bib-0022){ref-type="ref"} both reported that RARC had significantly lower estimated blood loss, lower transfusion rates and longer operative times compared with ORC. This is consistent with the benefit of robotic surgery for other disease entities, such as robotic radical prostatectomy.[48](#iju14005-bib-0048){ref-type="ref"} Another potential benefit of robotic surgery has been the shortened length of stay. However, we did not find any difference in the length of stay between RARC and ORC in RCTs, whereas NRCTs did report a shorter length of stay. This might be due to changes in postoperative pathways and the learning curve with a benefit to more modern pathways, such as ERAS, which is known to shorten the length of stay.[8](#iju14005-bib-0008){ref-type="ref"} Indeed, in many NRCTs, RARC was carried out in a more recent time period than ORC, leading to an experience and practice pattern change bias favoring the more recent technique.

We found that there was no difference in postoperative complications and mortality between RARC and ORC. Interestingly, this was true for complications within 30 and 90 days, and mortality within 90 days in RCTs. However, in NRCTs, the mortality rate within 90 days and the complication rate within 30 days were worse for ORC. This reporting deviation from NRCTs could be due to a selection, reporting and/or detection bias in favor of RARC. For example, several studies included ORC patients with higher comorbidities, higher BMI and/or more advanced disease compared with those treated with RARC, which led to a selection bias benefiting RARC.[7](#iju14005-bib-0007){ref-type="ref"}, [16](#iju14005-bib-0016){ref-type="ref"}, [18](#iju14005-bib-0018){ref-type="ref"}, [19](#iju14005-bib-0019){ref-type="ref"}, [26](#iju14005-bib-0026){ref-type="ref"}, [33](#iju14005-bib-0033){ref-type="ref"}, [37](#iju14005-bib-0037){ref-type="ref"} Furthermore, when comparing novel interventions with conventional ones, there can be a novelty bias in NRCTs, which is a form of selection bias.[49](#iju14005-bib-0049){ref-type="ref"}

There was no significant difference between RARC and ORC in the overall ileus rate in both RCTs and NRCTs. Additionally, postoperative health‐related QOL was not significantly different between RARC and ORC in both RCTs and NRCTs.

There are several limitations to be considered in this systematic review and meta‐analyses. There were just six RCTs included with a low number of patients, especially compared with NRCTs. However, all NRCTs were observational and retrospective, which can introduce selection bias. The operative time in RARC was reported including setting and console time in almost all eligible studies, therefore, we were not able to compare the exact operative time between console time and ORC. The definition of complications is slightly different among studies or not reported in several studies. The health‐related QOL assessment tools were very different between eligible studies. A surgeon\'s experience and expertise, which are only partially controlled in RCTs, were very different between studies, which might introduce a confounder.

Another limitation is the failure to report and control for the type and approach to the urinary diversion. Due to the heterogeneity regarding urinary diversion among eligible studies, we were not able to compare based on the type of urinary diversions. Furthermore, most urinary diversions described in RCTs and NRCTs of this meta‐analysis were carried out using ECUD, which might limit the benefits of RARC compared with ORC. Indeed, ICUD seems to have advantages in the postoperative complication rates and health‐related QOL after RARC compared with ECUD. Recently, in a retrospective study, Tan *et al*. showed the beneficial impact of RARC with ICUD using enhanced recovery protocols resulting in improved postoperative complication rates compared with ORC.[8](#iju14005-bib-0008){ref-type="ref"} However, this procedure requires a complicated surgical technique, which is only learned through a long learning curve. At this time, there is no prospective study to compare RARC with ICUD to RARC with ECUD or ORC.

Conclusions {#iju14005-sec-0016}
===========

RARC leads to less blood loss and lower transfusion rates compared with ORC; ORC is, in turn, associated with shorter operative times. Our systematic review and meta‐analyses did not show any difference between RARC and ORC in postoperative complications, mortality, and health‐related QOL in RCTs. NRCTs consistently reported better perioperative outcomes for RARC, such as shorter length of stay, mortality rate within 90 days and complication rate within 30 days, which were not confirmed in RCTs. These discrepancies could be due to bias in study design, measurement, selection and reporting. Further RCTs comparing postoperative complications and health‐related QOL between RARC with ICUD and ORC are required to assess potential benefits of RARC with the varied forms of urinary diversion.
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**Figure S1.** Risk of bias table for RCTs.
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**Figure S2.** Forest plot showing the comparison of mortality rates within 90 days between RARC and ORC.
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**Figure S3.** Forest plots showing the comparison of (a) rates for UTI, (b) rates for thromboembolisis, and (c) rates for ileus between RARC and ORC.
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**Table S1.** PRISMA 2009 checklist.
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**Table S2.** Risk of bias assessment for NRCTs (ROBINS‐I).
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